Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

770 cancer patients help unlock secrets of immunotherapy

NCT ID NCT03514368

First seen Feb 19, 2026 · Last updated May 19, 2026 · Updated 13 times

Summary

This study aims to find biological markers in blood and tumor samples that predict how well immunotherapy works and what side effects may occur. It will enroll 770 adults with advanced solid cancers like lung, head and neck, melanoma, or bladder cancer who are receiving immune checkpoint inhibitors. Researchers will collect samples at several time points and follow patients until their cancer progresses.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID CANCERS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chu Rangueil

    RECRUITING

    Toulouse, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hopital Larrey

    RECRUITING

    Toulouse, 31059, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Institut Universitaire Du Cancer de Toulouse - Oncopole

    RECRUITING

    Toulouse, 31059, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.